Get the Stockscreener App
6.90
23.25%
-2.09
Newamsterdam Pharma Company N V stock is traded at $6.90, with a volume of 4,199.
It is down -23.25% in the last 24 hours and down -34.91% over the past month.
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
See More
Previous Close:
$8.99
Open:
$8.42
24h Volume:
4,199
Relative Volume:
1.00
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-42.31%
1M Performance:
-34.91%
6M Performance:
-4.83%
1Y Performance:
-36.46%
1-Day Range:
$6.90
$8.42
1-Week Range:
$6.90
$12.24
52-Week Range:
$5.52
$16.75
Newamsterdam Pharma Company N V Stock (NAMSW) Company Profile
Name
Newamsterdam Pharma Company N V
Sector
Industry
Phone
31 35 206 2971
Address
Gooimeer 2-35, Naarden
Compare NAMSW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAMSW
Newamsterdam Pharma Company N V
|
6.90 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Newamsterdam Pharma Company N V Stock (NAMSW) Latest News
NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Leading Cardiovascular Drug Developer NewAmsterdam Sets Key Investor Presentation - Stock Titan
Newamsterdam Pharma CEO Michael Davidson sells shares for $281,000 By Investing.com - Investing.com Australia
Newamsterdam Pharma director James Topper buys $25,520 in shares By Investing.com - Investing.com Australia
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by Swiss National Bank - Defense World
Newamsterdam pharma COO sells shares worth $376,000 By Investing.com - Investing.com Canada
Newamsterdam Pharma CEO Michael Davidson sells shares for $281,000 - Investing.com India
Newamsterdam pharma COO sells shares worth $376,000 - Investing.com India
Newamsterdam Pharma COO Kling sells $2.36 million in stock By Investing.com - Investing.com Australia
Newamsterdam Pharma COO Kling sells $2.36 million in stock - Investing.com
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Sold by US Bancorp DE - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Receives $43.33 Consensus Price Target from Analysts - Defense World
Financial Metrics Exploration: Understanding NewAmsterdam Pharma Company NV (NAMS) Through Ratios - The Dwinnex
9,983 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Purchased by Keybank National Association OH - Defense World
A better buy-in window may exist right now for NewAmsterdam Pharma Company NV (NAMS) - SETE News
Newamsterdam pharma director James Topper buys $84,203 in shares By Investing.com - Investing.com Australia
Newamsterdam pharma director James Topper buys $84,203 in shares - Investing.com
New Amsterdam Pharma chief accounting officer sells $3.06 million in shares - Investing.com India
New Amsterdam Pharma chief accounting officer sells $3.06 million in shares By Investing.com - Investing.com South Africa
William Blair Has Negative Forecast for NAMS Q1 Earnings - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Price Target Raised to $52.00 - Defense World
(NAMS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib - Seeking Alpha
NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution (NASDAQ:NAMS) - Seeking Alpha
Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday? - AOL
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Yearly Results: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
NewAmsterdam Pharma’s 2024 Financial Results and Clinical Progress - TipRanks
7 Analysts Have This To Say About NewAmsterdam Pharma - Benzinga
Scotiabank raises NewAmsterdam Pharma target to $52 - Investing.com India
Scotiabank raises NewAmsterdam Pharma target to $52 By Investing.com - Investing.com South Africa
Newamsterdam Pharma Faces Potential Investor Risks Due to Shareholder Influence - TipRanks
NewAmsterdam Pharma's Full-Year Net Loss Widens, Revenue Rises -February 26, 2025 at 08:27 am EST - Marketscreener.com
Earnings Flash (NAMS) NewAmsterdam Pharma Posts Full Year 2024 Revenue $45.6M, vs. FactSet Est of $33.8M - Marketscreener.com
NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
NewAmsterdam Pharma Co N.V. SEC 10-K Report - TradingView
Can NewAmsterdam's Obicetrapib Reshape Cardiovascular Treatment? Phase 3 Results Show 49% LDL-C Reduction - StockTitan
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March - The Manila Times
NewAmsterdam Pharma Company N.V. (NAMS): Among the Oversold Biotech Stocks to Buy Now - Insider Monkey
10 Oversold Biotech Stocks to Buy Now - Insider Monkey
How to Take Advantage of moves in (NAMSW) - Stock Traders Daily
Newamsterdam Pharma Company N V Stock (NAMSW) Financials Data
There is no financial data for Newamsterdam Pharma Company N V (NAMSW). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.89%
0.13%
Cap:
|
Volume (24h):